Stock Events

Stock Events

Minerva Neurosciences 

€0.000000
0
+€0.00+0% 00:00 Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

4AugExpected
Q1 2026
Next
-2.44
-1.66
-0.89
-0.11
Expected EPS
-0.16910257511
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 4MN.MU. It's not an investment recommendation.
Microsoft
13
MSFT
Apple
12
AAPL
Tesla
12
TSLA
Amazon
12
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Acadia Pharmaceuticals
ACAD
Mkt Cap4.45B
Acadia Pharmaceuticals specializes in neurology, competing with Minerva in developing treatments for central nervous system disorders.
Alkermes
ALKS
Mkt Cap9.19B
Alkermes works on central nervous system (CNS) diseases, including schizophrenia and depression, areas Minerva is also targeting.
BridgeBio Pharma
BBIO
Mkt Cap15.12B
BridgeBio Pharma targets genetic diseases and precisely engineered drugs that could overlap with Minerva's focus on neurological conditions.
Biogen
BIIB
Mkt Cap31.91B
Biogen is a major player in neurology, directly competing with Minerva in the broader market for neurological disease treatments.
AMGEN
AMGN
Mkt Cap201.93B
Amgen, with its broad focus on biopharmaceuticals, has ventures into neuroscience, making it a competitor in the neurology space.
Insmed
INSM
Mkt Cap24.19B
Insmed incorporates a wide range of therapeutic areas, including neurological diseases, indirectly competing with Minerva.
Ionis Pharmaceuticals
IONS
Mkt Cap13.52B
Ionis Pharmaceuticals specializes in RNA-targeted drug discovery, which includes treatments for neurological disorders, competing with Minerva's focus.
Palatin Technologies
PTN
Mkt Cap20.62M
Palatin Technologies, though focused on different areas, has shown interest in expanding into central nervous system disorders, potentially competing with Minerva.

About

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase 3 confirmatory trial for the treatment of negative symptoms in patients with schizophrenia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.
Show more...
CEO
Dr. Remy Luthringer Ph.D.
Employees
7
Country
United States
ISIN
US6033801068

Listings

F
DE
4MNA.F
STU
DE
4MNA.STU
MU
DE
4MN.MU
MU
DE
4MNA.MU

0 Comments

Share your thoughts

FAQ

What is Minerva Neurosciences stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Muenchen exchange Minerva Neurosciences stocks are traded under the ticker 4MN.MU.
When is the next Minerva Neurosciences earnings date?▼
Minerva Neurosciences is going to release the next earnings report on August 04, 2026.
What were Minerva Neurosciences earnings last quarter?▼
4MN.MU earnings for the last quarter are -2.44 EUR per share, whereas the estimation was -0.11 EUR resulting in a -2,157.89% surprise. The estimated earnings for the next quarter are N/A EUR per share.
How many employees does Minerva Neurosciences have?▼
As of July 10, 2026, the company has 7 employees.
In which sector is Minerva Neurosciences located?▼
Minerva Neurosciences operates in the Health & Wellness sector.
When did Minerva Neurosciences complete a stock split?▼
Minerva Neurosciences has not had any recent stock splits.
Where is Minerva Neurosciences headquartered?▼
Minerva Neurosciences is headquartered in Burlington, United States.